

Pozelimab

Cat. No.:	HY-P99786
CAS No.:	2096328-94-6
Target:	Complement System
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases ^[1] .								
In Vitro	<p>Pozelimab binds with human C5 and cynomolgus monkey C5 with K_d values of 262 pM and 8.55 nM, respectively at 37 °C, pH7.4^[1].</p> <p>Pozelimab blocks classic pathway (CP)-mediated hemolysis in normal human and cynomolgus monkey serum with IC_{50} values of 2.8 and 20 nM, respectively at 37 °C, pH7.4^[1].</p> <p>Pozelimab blocks alternative pathway (AP)-mediated hemolysis in normal human and cynomolgus monkey serum with IC_{50} values of 26 and 8.9 nM, respectively at 37 °C, pH7.4^[1].</p> <p>Pozelimab binds to human C5, cynomolgus monkey C5, human R885C C5 and human C5b,6 with K_d values of 0.189, 2.73, 0.422, 0.465 and 0.137 nM respectively at 25 °C, pH7.4^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
In Vivo	<p>Pozelimab (15 mg/kg; s.c., once) has a prolonged pharmacokinetic (PK) with a half-life of approximately 13 days in male and female C5^{hu/hu} mice^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Cynomolgus monkey^[1]</td> </tr> <tr> <td>Dosage:</td> <td>15 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection; 15 mg/kg, once</td> </tr> <tr> <td>Result:</td> <td>Showed a a greater exposure to monkeys compared with H4H12161P and H4H12170P.</td> </tr> </table>	Animal Model:	Cynomolgus monkey ^[1]	Dosage:	15 mg/kg	Administration:	Intravenous injection; 15 mg/kg, once	Result:	Showed a a greater exposure to monkeys compared with H4H12161P and H4H12170P.
Animal Model:	Cynomolgus monkey ^[1]								
Dosage:	15 mg/kg								
Administration:	Intravenous injection; 15 mg/kg, once								
Result:	Showed a a greater exposure to monkeys compared with H4H12161P and H4H12170P.								

REFERENCES

[1]. Latuszek A, et al. Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5. PLoS One. 2020 May 8;15(5):e0231892.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA